<DOC>
	<DOCNO>NCT00159055</DOCNO>
	<brief_summary>Treatment strategy patient : Stem cell engraftment ( myeloablative NST ) induction host v graft myeloablative transplantation tolerance . Whenever indicate , additional post NST DLI give grade increment , optimize control GVHD . Preparation immune donor lymphocytes , either donor immunization in-vitro CMV-specific peptide follow administration immunize donor lymphocyte , injection donor lymphocytes in-vivo sensitization donor lymphocytes patient follow DLI . Pre-emptive treatment seronegative patient risk patient document viremia CMV disease CMV-specific donor lymphocyte generate in-vivo donor host peptide immunization . Consenting donor immunize CMV-specific peptide , induction CTLs in-vivo follow subcutaneous inoculation peptide adjuvant donor APC pulse relevant peptide .</brief_summary>
	<brief_title>Adoptive Immunotherapy CMV Disease</brief_title>
	<detailed_description />
	<criteria>For Patient : Consenting patient indication myeloablative BMT NST HLA match sibling available , transplant . Patients risk CMV disease include seronegative patient ; patient seronegative donor , seronegative donor sero positive patient . Patients resistant CMV viremia CMV disease respond conventional treatment ganciclovir , Foscarnet . Patients HLA phenotype relevant peptide CMV exists . For Donor : Consenting sibling &gt; 18 year old . HLA phenotype relevant peptide CMV exists . For Patient : Patients severe resistant GVHD may risk administer DLI immunize donor lymphocyte . For Donor : Consenting sibling &gt; 18 year old . HLA phenotype relevant peptide CMV exists . Donor infectious disease ( e.g . HIV1 ; HBV , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>